Lilly’s 12th deal adds yet another modality to the most diversified pipeline build in pharmaceutical history. The company signed a collaboration worth up to $1.9 billion with Ascidian Therapeutics to develop RNA exon editing therapeutics for genetic kidney diseases. RNA exon editing is distinct from CRISPR, base editing, and the recombinase approaches Lilly licensed from Profluent. It works at the RNA level—no permanent DNA changes—correcting genetic defects by modifying messenger RNA before it is translated into protein. The deal adds an eighth modality to Lilly’s 2026 portfolio and brings total announced value above $30 billion across 12 deals in under six months. Separately, Bristol Myers Squibb announced a partnership with Anthropic to apply Claude AI across drug development workflows. BMS joins Sanofi, Novo Nordisk, AbbVie, and Novartis (CEO Narasimhan sits on the board) as pharma companies integrating Anthropic’s platform—meaning five of the top ten global pharma companies by revenue are now working with Anthropic in some capacity. Moderna partnered to develop a vaccine targeting the Bundibugyo Ebola strain responsible for the ongoing WHO PHEIC. And Lilly and Boehringer Ingelheim each slashed planned investments in Germany by at least $1 billion in response to a healthcare reform initiative.
Top Story: Lilly’s 12th Deal — $1.9B RNA Exon Editing for Kidney Disease
What Happened: Lilly signed a collaboration with Ascidian Therapeutics worth up to $1.9 billion in milestones to develop RNA exon editing therapeutics for genetic kidney diseases.
What RNA Exon Editing Is and Why It Matters
RNA exon editing modifies messenger RNA to correct genetic defects without making permanent changes to DNA. The approach works by recruiting the cell’s own splicing machinery to include or exclude specific exons—segments of the genetic code—from the mRNA transcript. This produces a corrected protein without altering the patient’s genome.
The distinction from other genetic medicine approaches is important. CRISPR makes permanent cuts to DNA, which is powerful but irreversible and carries theoretical risks of off-target editing and insertional oncogenesis (as highlighted by the AAV-linked brain tumor case reported earlier this month). Base editing makes permanent single-letter changes to DNA—more precise than CRISPR but still irreversible. Recombinases (Profluent, Lilly’s April deal) insert entire genes permanently into the genome.
RNA exon editing occupies a fundamentally different space. Because the changes occur at the RNA level rather than the DNA level, the effects are reversible and titratable. If the dose is stopped, the correction stops. If the dose is reduced, the correction diminishes proportionally. For chronic diseases where long-term dosing adjustments may be needed, this offers a flexibility that permanent DNA editing cannot match.
Why Kidney Disease Is the Right First Target
Genetic kidney diseases represent a significant unmet need with well-characterized genetic causes. Many forms of hereditary kidney disease are caused by specific mutations that produce dysfunctional proteins in kidney cells. RNA exon editing can potentially correct these mutations at the mRNA level, restoring functional protein production without permanent genetic modification.
The kidney is also a therapeutically accessible organ. Multiple drug delivery modalities can reach kidney cells effectively, making it a favorable target for RNA-based therapeutics that need to reach their site of action. For Lilly, genetic kidney disease represents a patient population that is small but clinically defined, with clear genetic targets and no existing curative therapies—the ideal profile for a precision genetic medicine.
The $1.9 billion milestone structure signals that Lilly sees franchise-level potential in the approach. Milestone payments of that magnitude are typically reserved for programs with blockbuster commercial expectations, not for exploratory research partnerships.
Lilly’s 2026 Deal Campaign: The Numbers
This is Lilly’s 12th deal of 2026. Total announced value now exceeds $30 billion across under six months. The deals span eight distinct modalities: GLP-1 obesity (Foundayo, Zepbound), in vivo CAR-T (Kelonia, Orna), narcolepsy (Centessa), ADCs (CrossBridge), targeted oncology (Ajax JAK2), AI gene editing (Profluent recombinases), non-viral DNA delivery (Engage), vaccines (Curevo shingles, LimmaTech AMR, Vaccine Company EBV), China licensing (Haisco five programs), and now RNA exon editing (Ascidian kidney).
No other pharmaceutical company has attempted this volume, breadth, and pace of dealmaking in a comparable timeframe. The December 7 Investment Community Meeting will be the most consequential strategic presentation in Lilly’s history. Management will need to demonstrate that the organizational bandwidth exists to integrate and advance 12 partnerships simultaneously while running the Foundayo launch, the Zepbound/Mounjaro franchise, and the retatrutide TRIUMPH program.
Our Pro brief includes the complete 12-deal running total with individual values, modality mapping, and an assessment of whether organizational bandwidth supports this level of simultaneous activity. [Details below.]
BMS Partners with Anthropic on AI Drug Development
What Happened: Bristol Myers Squibb announced a partnership with Anthropic to apply Claude AI across drug development workflows. BMS now joins a growing roster of pharmaceutical companies working with Anthropic: Sanofi, Novo Nordisk, AbbVie, and Novartis (CEO Narasimhan sits on Anthropic’s board).
Five of the Top Ten Pharma Companies Are Now Working with Anthropic
With BMS joining, five of the top ten global pharmaceutical companies by revenue are now working with Anthropic in some capacity. No other AI company has this depth of pharma integration. The roster spans immunology (AbbVie), oncology and hematology (BMS), metabolic disease (Novo Nordisk), vaccines and immunology (Sanofi), and multi-therapeutic (Novartis).
Anthropic’s pharma strategy has evolved rapidly in 2026. The $400 million Coefficient Bio acquisition in April brought biology-native AI expertise in-house. Narasimhan’s board appointment at Novartis added pharma governance. The Gates Foundation partnership extended the platform into global health. And now BMS’s partnership pushes Claude into the hematology and oncology pipeline space where BMS has its deepest expertise and greatest commercial investment.
What AI Drug Development Actually Means in Practice
The practical applications of AI in drug development are moving beyond the theoretical. Companies are deploying AI platforms for target identification (predicting which biological targets are most likely to produce therapeutic benefit), molecular design (generating and optimizing drug candidates computationally), clinical trial optimization (designing more efficient trials, predicting patient enrollment, and identifying optimal endpoints), and regulatory document preparation (accelerating the preparation of NDA and BLA submissions).
For BMS, which is managing the Revlimid and Eliquis patent cliff while building a next-generation pipeline through the Hengrui partnership ($15.2 billion, 13 programs) and internal development, AI-driven efficiency gains across the development process could compress timelines and reduce costs at precisely the moment when both matter most. The company’s pipeline spans oncology and hematology, two of the most data-intensive therapeutic areas in medicine, where the volume of clinical, genomic, and real-world data available for AI analysis is enormous.
The broader signal is clear: AI in pharma is transitioning from an experimental technology to an operational standard. The five-of-ten-top-pharma integration rate suggests that within two to three years, AI-powered drug development workflows will be the norm rather than the exception across the industry. Companies that are not integrating AI into their development processes now will face a competitive disadvantage as their peers compress timelines and improve decision-making through computational tools that augment human expertise rather than replacing it.
Moderna Partners on Bundibugyo Ebola Vaccine
What Happened: Moderna linked up with a global vaccine foundation to develop a vaccine targeting the Bundibugyo Ebola strain, directly addressing the WHO PHEIC declared May 17.
Addressing the Countermeasure Gap
When the WHO declared the Bundibugyo PHEIC, we noted that no approved vaccines or therapeutics exist for this strain. Every Ebola countermeasure developed over the past two decades targets the Zaire strain. The Bundibugyo variant is genetically distinct enough that existing products (Merck’s Ervebo, Regeneron’s Inmazeb) are not expected to cross-protect.
Moderna’s mRNA platform is theoretically among the fastest to redirect to a new pathogen target. The technology can generate a Bundibugyo-specific vaccine construct by encoding the viral surface proteins of the Bundibugyo strain into an mRNA sequence, which the patient’s own cells then use to produce the viral proteins and generate an immune response. The speed advantage of mRNA over traditional vaccine approaches—which require growing viral components in cell culture or using attenuated virus—could compress the development timeline from years to months.
This follows Lilly’s acquisition of three vaccine companies in May (Curevo, LimmaTech, Vaccine Company) and reflects a broader industry mobilization around infectious disease prevention. The Ebola PHEIC continues in the DRC and Uganda with confirmed cross-border spread. As of the most recent reports, the outbreak involves 8 confirmed cases, 246 suspected cases, and 80 suspected deaths in the DRC, with confirmed cases in Uganda. The need for Bundibugyo-specific countermeasures remains urgent.
Lilly and Boehringer Slash German Investments by $1B+ Each
What Happened: Lilly and Boehringer Ingelheim each cut planned investments in Germany by at least $1 billion in response to a healthcare reform initiative.
Why This Matters Beyond Germany
Germany is the largest pharmaceutical market in Europe. The investment pullback signals how quickly pharmaceutical companies will redirect capital when pricing reforms threaten returns. Both Lilly and Boehringer had made commitments to expand manufacturing and R&D facilities in Germany. Those commitments have been reduced by a combined $2 billion-plus in response to policy changes that compress the revenue those investments were designed to generate.
The timing is significant. The EU Critical Medicines Act (agreed May 22) is designed to strengthen European pharmaceutical supply chains through domestic manufacturing incentives. But the Germany pricing reform moves in the opposite direction—compressing the margins that fund manufacturing investment. The two policies are structurally in tension.
For multinational pharma companies, the message is clear: capital flows to markets where the policy environment supports investment returns. The United States, despite the MFN pricing framework and Section 232 tariffs, continues to offer pricing and reimbursement dynamics that are more favorable than most European markets. The Germany pullback, combined with the Indian pharma companies’ $19.1 billion in U.S. manufacturing pledges and the CordenPharma/AmbioPharm acquisition for U.S. peptide supply, suggests that pharmaceutical manufacturing investment is increasingly flowing toward the United States and away from markets implementing aggressive pricing reform.
CDMO Deal: CordenPharma Acquires AmbioPharm for U.S. Peptide Supply
Swiss CDMO CordenPharma agreed to acquire AmbioPharm, gaining peptide manufacturing facilities including a plant in South Carolina that provides fully U.S.-based supply capability. The deal is relevant for GLP-1 manufacturing and other peptide therapeutics, aligning with the Section 232 tariff framework’s emphasis on domestic pharmaceutical production and the industry’s broader push to build tariff-advantaged U.S. supply chains. With the Medicare GLP-1 Bridge program launching July 1 and injectable GLP-1 demand continuing to grow, domestic peptide manufacturing capacity is becoming a strategic asset. The deal joins the MacroGenics/Bora manufacturing divestiture and the Indian pharma $19.1 billion in U.S. manufacturing pledges as evidence that pharmaceutical production infrastructure is migrating toward the United States at an accelerating pace.
Strategic Themes
1. Lilly at 12 Deals and $30B+ Is Rewriting the Rules of Pharmaceutical M&A
No precedent exists for what Lilly is doing. Twelve deals across eight modalities in six months, totaling more than $30 billion. The company is not acquiring a single transformative asset—it is building a diversified platform across the full spectrum of modern therapeutic modalities, from small molecules to cell therapy to vaccines to gene editing to RNA editing. Whether this produces a pharmaceutical company with unmatched breadth or an organization that is spread too thin to execute on any single opportunity is the question that will define Lilly’s trajectory for the next decade.
2. Anthropic Is Becoming the Default AI Platform for Pharma
Five of the top ten. The integration rate is remarkable for a technology that was experimental in pharma just two years ago. Anthropic’s strategy—acquisition (Coefficient Bio), governance (Narasimhan board seat), partnerships (Sanofi, Novo, AbbVie, BMS), and global health (Gates Foundation)—is positioning Claude as the AI operating system for pharmaceutical R&D. The competitive implications for other AI companies seeking pharma partnerships are significant: Anthropic’s breadth of integration creates switching costs and data advantages that will be difficult for competitors to replicate.
3. The Germany Pullback Shows How Pharma Capital Responds to Pricing Reform
$2 billion-plus in investment withdrawn from Europe’s largest pharma market. The speed of the response—both Lilly and Boehringer reacted to the reform initiative rather than waiting for implementation—demonstrates that pharmaceutical capital allocation is extremely sensitive to pricing policy signals. Governments seeking to attract pharmaceutical manufacturing investment and R&D spending must balance their desire for lower drug prices against the reality that pricing compression reduces the returns that attract investment in the first place.
4. The Moderna Ebola Vaccine Addresses the Most Urgent Gap in Global Health Today
The Bundibugyo PHEIC continues with no approved countermeasures. Moderna’s mRNA platform offers the fastest path to a strain-specific vaccine. The partnership demonstrates that the pharmaceutical industry can mobilize against novel pathogen threats—but the timeline from partnership announcement to clinical testing to emergency authorization is measured in months, not days. The question is whether the outbreak trajectory allows enough time for the vaccine development process to produce a usable product.
Frequently Asked Questions
What is the Ascidian deal?
Lilly signed a collaboration worth up to $1.9 billion with Ascidian Therapeutics to develop RNA exon editing therapeutics for genetic kidney diseases. RNA exon editing corrects genetic defects at the mRNA level without permanent DNA changes. This is Lilly’s 12th deal of 2026 and its eighth modality.
What is RNA exon editing?
A technology that modifies messenger RNA to correct genetic defects by including or excluding specific exons from the mRNA transcript. Unlike CRISPR and base editing, the changes are reversible and titratable because they occur at the RNA level, not the DNA level. If dosing stops, the correction stops.
What is the BMS/Anthropic partnership?
BMS will apply Claude AI across drug development workflows. BMS joins Sanofi, Novo Nordisk, AbbVie, and Novartis as the fifth top-ten pharma company working with Anthropic. Anthropic also acquired Coefficient Bio ($400M, April) and partnered with the Gates Foundation (May).
What is Moderna doing about Ebola?
Partnering with a global vaccine foundation to develop an mRNA vaccine targeting the Bundibugyo Ebola strain. No approved vaccines exist for Bundibugyo. Moderna’s mRNA platform can potentially generate a strain-specific construct faster than traditional vaccine approaches.
Why did Lilly and Boehringer cut German investments?
In response to a healthcare reform initiative that compresses pharmaceutical pricing and returns in Germany. Each company cut at least $1 billion in planned investment. The moves signal how sensitive pharma capital allocation is to pricing policy changes.
What is the CordenPharma/AmbioPharm deal?
Swiss CDMO CordenPharma is acquiring AmbioPharm to gain U.S.-based peptide manufacturing capability, including a South Carolina plant. The deal supports GLP-1 and peptide supply chain domestication under the Section 232 tariff framework.
How many deals has Lilly done in 2026?
Twelve. Total announced value exceeds $30 billion across eight distinct modalities and seven therapeutic areas in under six months.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
RNA Exon Editing. We analyze how Ascidian’s approach differs from CRISPR, base editing, and recombinases at the molecular level, why the reversibility of RNA editing creates advantages for chronic disease, and what the $1.9B milestone structure implies about Lilly’s commercial expectations for genetic kidney disease.
Anthropic’s Pharma Ecosystem. We compile the full map of Anthropic’s pharmaceutical relationships—Coefficient Bio, Narasimhan board seat, Gates Foundation, Sanofi, Novo, AbbVie, BMS—and assess what having five of the top ten pharma companies on the platform means for AI drug development adoption across the industry.
Germany Investment Pullback. We analyze what Lilly and Boehringer’s $2B+ withdrawal signals for EU pharmaceutical policy, how the pricing reform interacts with the Critical Medicines Act’s supply chain objectives, and where the redirected capital is most likely to flow.
Plus: Moderna Ebola timeline, CordenPharma peptide supply analysis, 340B compliance watch, Revolution filing status, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
